Medistim ASA
Medistim ASA (0OCD.L) Financial Performance & Income Statement Overview
Analyze Medistim ASA (0OCD.L) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Medistim ASA (0OCD.L) Income Statement & Financial Overview
Analyze Medistim ASA’s 0OCD.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $151.14M | $132.75M | $144.92M | $133.79M |
| Cost of Revenue | $33.59M | $77.82M | $75.22M | $77.39M |
| Gross Profit | $117.55M | $54.94M | $69.70M | $56.40M |
| Gross Profit Ratio | $0.78 | $0.41 | $0.48 | $0.42 |
| R&D Expenses | $0.00 | $9.70M | $6.40M | $8.10M |
| SG&A Expenses | $0.00 | $13.33M | $22.04M | $16.23M |
| Operating Expenses | $91.71M | $23.03M | $28.44M | $24.33M |
| Total Costs & Expenses | $125.30M | $100.85M | $103.66M | $101.72M |
| Interest Income | $5.84M | $61000.00 | $3.40M | $3.58M |
| Interest Expense | $467000.00 | $0.00 | $87000.00 | $4.99M |
| Depreciation & Amortization | $6.54M | $5.20M | $6.43M | $6.34M |
| EBITDA | $35.31M | $35.82M | $45.21M | $38.41M |
| EBITDA Ratio | $0.23 | $0.27 | $0.31 | $0.29 |
| Operating Income | $25.84M | $31.91M | $41.26M | $32.07M |
| Operating Income Ratio | $0.17 | $0.24 | $0.28 | $0.24 |
| Other Income/Expenses (Net) | $2.46M | -$1.29M | $3.40M | -$1.40M |
| Income Before Tax | $28.30M | $30.62M | $44.66M | $30.66M |
| Income Before Tax Ratio | $0.19 | $0.23 | $0.31 | $0.23 |
| Income Tax Expense | $7.00M | $7.19M | $9.94M | $6.28M |
| Net Income | $21.30M | $23.43M | $34.72M | $24.38M |
| Net Income Ratio | $0.14 | $0.18 | $0.24 | $0.18 |
| EPS | $1.16 | $1.28 | $1.90 | $1.33 |
| Diluted EPS | $1.16 | $1.28 | $1.90 | $1.33 |
| Weighted Avg Shares Outstanding | $18.31M | $18.31M | $18.31M | $18.31M |
| Weighted Avg Shares Outstanding (Diluted) | $18.31M | $18.31M | $18.31M | $18.31M |
Over the last four quarters, Medistim ASA's revenue moved from $133.79M in Q1 2024 to $151.14M in Q4 2024. Operating income in Q4 2024 was $25.84M, with a strong operating margin of 17%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Medistim ASA remained robust at $35.31M, reflecting operational efficiency. Net income dropped to $21.30M, with an EPS of $1.16. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan